Novartis

Novartis

Web: Novartis external link
Location: Basel
Discipline: Medicine/Pharmacology
Related to:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.
#display_name

Medicine Aug 25
The Phase III EXPAND study of BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS) met its primary endpoint of reducing the risk of three-month confirmed disability progression versus placebo There are currently very limited treatment options for SPMS, a form of MS associated with gradual worsening of symptoms and accum
Medicine Aug 15

The Basic Immunology Prize is awarded to John Kappler, Philippa Marrack and Harald von Boehmer for demonstrating that the ability of the immune system to discriminate "self" from "non-self" is acquired in the thymus.

Medicine Aug 2

US Food and Drug Administration (FDA) grants approval for CyPass Micro-Stent for sale in the US, expanding Alcon's surgical presence to treat glaucoma -   The CyPass Micro-Stent is designed t

Medicine Jul 14

Presbyopia is an eye condition that is part of natural aging affecting nearly 2 billion people worldwide.

Medicine Aug 3

Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer Designation underscores the continuing un

Business Jul 19

Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects - Q2 net sales were flat (0% cc ) as Growth

Medicine Jul 13

Committee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product                                                             



website preview

Link

Medicine and Life Sciences